Introduction
============

The term "idiopathic polypoidal choroidal vasculopathy" (IPCV) was coined by Yannuzzi et al to describe a disease of the choroidal circulation characterized by branching choroidal vessels with polyp-like terminal aneurysmal dilations, and recognized as a clinical entity separate from age-related macular degeneration.[@b1-opth-4-1237] The vascular abnormalities are frequently located in the peripapillary area or within the macula, where they may be responsible for serious visual loss. Large serous-hemorrhagic pigmented epithelial detachments (PEDs) are another clinical characteristic of the disease.[@b3-opth-4-1237] IPCV is not a rare condition among patients presumptively diagnosed with exudative age-related macular degeneration (7.9% of 167 patients in a mixed population).[@b2-opth-4-1237] Both sexes are equally affected, but a predilection for more darkly pigmented patients has been observed, although white patients still represent the majority of polypoidal choroidal vasculopathy patients in clinical practice.[@b1-opth-4-1237],[@b2-opth-4-1237]

Treatment for IPCV is not yet well established. A conservative approach is recommended, unless the lesion is associated with persistent or progressive exudative change, threatening central vision.[@b4-opth-4-1237] In this case, conventional thermal laser treatment of the leaking polypoidal choroidal vascular abnormality may be successful in causing resolution of the serous-hemorrhagic manifestations. In the more compromised varieties, photodynamic therapy (PDT) with verteporfin has demonstrated promising results,[@b5-opth-4-1237],[@b6-opth-4-1237] although definitive outcomes to confirm these anecdotal observations are not yet available. We herein report the clinical course of 10 consecutive patients affected by IPVC in whom the efficacy and safety of PDT plus intravitreal bevacizumab (IVB) injection has been analyzed.

Materials and methods
=====================

Our series consisted of 10 eyes of 10 consecutive patients (aged 68.7 ± 13 years, male to female ratio 7:3) diagnosed with IPCV and subfoveal involvement, who were refractory to previous treatment with photodynamic therapy alone. Demographic characteristics for the patients are summarized in [Table 1](#t1-opth-4-1237){ref-type="table"}. The diagnosis of IPCV was based on clinical examination and on multiple areas of PED seen on indocyanine green angiograms (ICGA) as a network of branching vessels and polypoidal lesions in the macular area located at the margin of the PEDs. All patients underwent a complete ophthalmic examination including fluorescein angiography, ICGA, and optical coherence tomography (OCT) at baseline and at one, three, six, nine, and 12 months of follow-up. Best-corrected visual acuity (BCVA) was measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.

PDT followed by IVB (1.25 mg/0.05 mL) injection two weeks later were performed in all cases. Two adjunctive injections of bevacizumab were scheduled at four and eight weeks after the initial treatment. The patients were given detailed information about the natural course of the disease and about the results of alternative therapeutic and surgical approaches for IPCV before being offered IVB. Written informed consent was obtained from all subjects after a description of the procedure to be used. The local human subjects review committees (Brescia, Campobasso, Larino, Napoli) approved the project.

Results
=======

Five patients were phakic and five were pseudophakic. Baseline BCVA ranged from 20/400 to 20/100. BCVA, macular thickness, and angiographic variations during the 12 months of follow-up are detailed in [Table 2](#t2-opth-4-1237){ref-type="table"}. A neurosensory retinal detachment and at least one PED were observed at baseline in all recruited patients.

After the third IVB injection, angiography showed a regression in size of the polypoidal vascular lesions and a reduction in leakage. OCT scans documented an improvement in neurosensory retinal detachment and a reduction of PED ([Figures 1](#f1-opth-4-1237){ref-type="fig"} and [2](#f2-opth-4-1237){ref-type="fig"}). In five cases (patients 2, 5, 6, 8, and 10), both retinal and choroidal angiograms did no longer show signs of vascular activity. In four cases (patients 1, 4, 7, and 9), the PED was no longer visible at slit-lamp examination or fluorescein angiography, and the choroidal neovascularization also seemed to have decreased, with involution of the choroidal polyp-like structure, together with a minimal residual leakage (area of leakage occupying \<50% of the area noted at baseline). In one case (patient 3), no signs of regression, in terms of reduction in leakage or size of the lesion, could be seen at 12-month follow-up after combined therapy.

Regression of macular thickness, assessed by OCT examination, occurred in all the patients and remained stable over the entire follow-up period. In fact, after one month of PDT, the mean reduction in macular thickness was about 30%. At the end of the 12-month follow-up, a modest further increase of about 40% was documented ([Table 2](#t2-opth-4-1237){ref-type="table"}). The treatment was not able to ameliorate VA significantly, which remained unwaivering at each assessment. No side effects were reported due to the combined treatment.

Discussion
==========

Polypoidal choroidal vasculopathy seems to be a distinct clinical entity that should be differentiated from other types of occult choroidal neovascularization associated with age-related macular degeneration and other known choroidal degenerative, inflammatory, and ischemic disorders. The principal abnormality seen in IPCV, notably the branching vascular network and polypoidal structures at the borders of the lesion, seem to be unique to the disorder.

In this prospective interventional case series, the combination of PDT and IVB has been able to treat the lesion in patients affected by IPCV. A potential benefit in terms of stabilization of leakage and lesion size was documented, but it was not associated with significant recovery of visual acuity. The PDT-IVB combination led to a rapid decrease in macular thickness, with a significant regression in terms of retinal edema and subretinal fluid, being successful in stabilizing the lesion. IPCV has been reported in 85% of patients with PED, subretinal hemorrhages, and exudation in the macular area on ICGA in patients with hemorrhagic AMD.[@b3-opth-4-1237] The most frequent clinical complication after treatment could be the exudative retinal detachments, retinal pigment epithelium tears, and massive bleeding.

In patients with serous-sanguineous detachment of the pigment epithelium, particularly those with increased risk factors, such as African-American or Asian race, ICGA should be performed to evaluate the choroidal vascular abnormality in an attempt to establish a more definitive diagnosis. If the characteristic vascular lesion of IPCV is seen, a conservative approach should be entertained unless there is a persistent or progressive exudative change that is threatening the central macula. In that event, there may be a rationale for photocoagulation treatment of leaking aneurysmal or polypoidal components within the vascular lesion, but not the entire vascular complex.[@b4-opth-4-1237]

Several experimental treatments, such as focal laser photocoagulation, thermal laser, and PDT have demonstrated only a potential success rate with several complications. Laser photocoagulation and thermal laser are advised for the treatment of IPCV if the lesion does not involve the fovea. This treatment is actually considered a palliative treatment for IPCV, and the final vision achieved is poor and relapse is frequent.[@b4-opth-4-1237],[@b5-opth-4-1237] PDT with verteporfin for IPCV involving the fovea appears to be a viable option, but the treatment could be complicated by iatrogenic bullous exudative retinal detachments that resemble rhegmatogenous detachments[@b6-opth-4-1237] or by the risk of massive bleeding. Moreover, as demonstrated in the Verteporfin in Photodynamic Therapy study, the visual outcome of PDT for occult choroidal neovascularization in age-related macular degeneration was generally compromised, because more than 50% of verteporfin-treated eyes developed visual loss of three or more lines after one year.[@b7-opth-4-1237]

Bevacizumab is a mouse-derived monoclonal antibody designed to neutralize the effects of all isoforms of vascular endothelial growth factor (VEGF). It plays a role as a choroidal survival factor for the choriocapillaris, maintaining the permeability and fenestration of the vessels. This antigen-binding monoclonal antibody has never been tested before for the treatment of occult choroidal neovascularization characterized by polyp-like vessels.

One of the reasons for the less favorable outcome in treating an occult lesion such as IPCV might be the collateral damage to adjacent structures, such as choriocapillaris hypoperfusion and retinal pigment epithelium atrophy, due to the effect of PDT.[@b8-opth-4-1237] The associated damage results in retinal edema and release of angiogenic factors, with reduction of retinal function demonstrated by multifocal electroretinography.[@b9-opth-4-1237]

Therefore, after an unsuccessful single treatment with PDT alone, we thought that adding anti-VEGF treatment might increase the efficacy of PDT in the treatment of this particular kind of choroidal neovascularization. Because the antiangiogenic effects of PDT with verteporfin are usually transient, a combination of PDT with an intermediate-acting antiangiogenic agent like IVB may be a promising treatment option by creating a longer lasting and possibly synergistic effect on choroidal neovascularization.

The first case report described the clinical course of a patient treated with IVB, who had received prior treatments with PDT and intravitreal pegaptanib with a poor therapeutic response.[@b10-opth-4-1237] Within four weeks of follow-up after a single IVB, an improvement of VA for hand motion to 20/400 coincident with resolution of subretinal fluid was achieved. Moreover, the macula remained without exudation for 12 months post treatment.

The first reported series consisted of 11 IPCV patients treated with IVB and a three-month follow-up.[@b11-opth-4-1237] An additional injection was administered in five of 11 eyes. The main outcomes were changes in the polypoidal vessels, foveal height, and BCVA, evaluated before and three months after treatment. At month 3, a resolution of polyps had occurred in one eye, whereas residual or enlarged lesions were recorded in the other 10 eyes. The foveal height decreased significantly one month after IVB, but at three months no significant decrease was observed, although an additional injection had been performed. The BCVA did not improve significantly. The conclusion of the study was that IVB may reduce the fluid from choroidal vasculopathy but seems to be ineffective for diminishing its choroidal vascular changes.

Sato et al described 12-month follow-up results for 29 treatment-naïve IPCV patients who received combined therapy (IVB-PDT-verteporfin). The mean number of treatments with combined therapy averaged 1.59. Polypoidal lesions recurred in six eyes (21%). The authors concluded that the combined treatment seemed to be effective for improving visual acuity and reducing retreatment rates and complications. [@b12-opth-4-1237] In contrast, Lim et al showed 12-month results for 10 eyes affected by IPCV and randomized to either IVB or combined treatment. IVB alone had similar efficacy and safety to IVB plus PDT for treatment of patients, including those who were treatment-naïve.[@b13-opth-4-1237]

In our study, the combined treatment led to morphologic stabilization of IPCV lesions, seen as a rapid decrease in macular thickness together with a regression of the size of polypoidal vascular lesions, but this was not accompanied by an increase in BCVA.

There are several important limitations to this study, including lack of a control group, a small number of patients, and inadequate low functional changes measurement. The encouraging results obtained in these patients emphasize the need for further randomized clinical studies of combined treatment for IPCV lesions.
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![**A** fluorescein, **B** indocyanine green, early phase, **C** indocyanine green, later phase baseline angiographic characteristics. The angiograms showed choroidal polyp-like structure together with subfoveal leakage. **D** fluorescein angiography, **E** indocyanine green, early phase, **F** indocyanine green, later phase at 12-months follow-up. The angiograms showed a regression in size of the polypoidal vascular lesions and a reduction in leakage.](opth-4-1237f1){#f1-opth-4-1237}

![At 12-month follow-up, the opical coherence tomography scans showed an improvement of neurosensory retinal detachment and a reduction of pigment endothelial detachment **B** from baseline **A**.](opth-4-1237f2){#f2-opth-4-1237}

###### 

Baseline patient characteristics undergoing intravitreal bevacizumab treatment for a polypoidal choroidal vascular lesion

  Patient   Gender   Age   Eye     Lens status    Visual acuity
  --------- -------- ----- ------- -------------- ---------------
  1         M        54    Right   Phakic         20/120
  2         M        63    Left    Phakic         20/100
  3         F        77    Right   Pseudophakic   20/120
  4         M        88    Right   Pseudophakic   20/400
  5         M        80    Left    Pseudophakic   20/200
  6         M        78    Right   Pseudophakic   20/400
  7         F        57    Right   Phakic         20/400
  8         M        53    Left    Phakic         20/200
  9         F        65    Right   Phakic         20/120
  10        M        71    Right   Pseudophakic   20/200

###### 

Best-corrected visual acuity and macular thickness variation during 12 months of follow-up after intravitreal bevacizumab treatment for a polypoidal choroidal vascular lesion

  Patient number   Visual acuity   Macular thickness   Last FA                                                                  
  ---------------- --------------- ------------------- --------- -------- -------- -------- ----- ----- ----- ----- ----- ----- --------------------------------------------------
  1                20/120          20/80               20/80     20/80    20/100   20/100   380   210   220   210   210   210   Min
  2                20/100          20/100              20/100    20/100   20/100   20/100   410   240   230   230   220   220   No leakage
  3                20/120          20/80               20/100    20/100   20/120   20/120   460   320   300   285   280   280   Prev[\*](#tfn1-opth-4-1237){ref-type="table-fn"}
  4                20/400          20/100              20/200    20/100   20/120   20/100   370   320   320   290   260   260   Min+
  5                20/200          20/100              20/80     20/80    20/80    20/80    380   290   210   210   220   220   No leakage
  6                20/400          20/200              20/200    20/100   20/80    20/80    320   240   220   220   215   215   No leakage
  7                20/400          20/100              20/100    20/80    20/100   20/80    340   260   230   230   230   230   Min
  8                20/200          20/80               20/60     20/80    20/80    20/80    350   210   230   230   220   220   No leakage
  9                20/120          20/120              20/100    20/80    20/80    20/80    440   300   260   240   210   210   Min
  10               20/200          20/200              20/200    20/120   20/120   20/100   390   270   260   260   290   280   No leakage

**Note:** Prev = area of leakage occupying \>50% of the area noted at baseline; + Min = area of leakage occupying \<50% of the area noted at baseline.

**Abbreviation:** FA, fluorescein angiography.
